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Estrogens play a pivotal role in the development and proliferation of hormone-dependent
breast cancer. Apart from free estrogens, which can directly activate the estrogen
receptor (ER) of tumor cells, sulfo-conjugated steroids, which maintain high plasma
concentrations even after menopause, first have to be imported into tumor cells by
carrier-mediated uptake and then can be cleaved by the steroid sulfatase to finally
activate ERs and cell proliferation. In the present study, expression of the sodium-
dependent organic anion transporter SOAT was analyzed in breast cancer and its
role for hormone-dependent proliferation of T47D breast cancer cells was elucidated.
The SOAT protein was localized to the ductal epithelium of the mammary gland
by immunohistochemistry. SOAT showed high expression in different pathologies of
the breast with a clear ductal localization, including ductal hyperplasia, intraductal
papilloma, and intraductal carcinoma. In a larger breast cancer cDNA array, SOAT
mRNA expression was high in almost all adenocarcinoma specimen, but expression
did not correlate with either the ER, progesterone receptor, or human epidermal growth
factor receptor 2 status. Furthermore, SOAT expression did not correlate with tumor
stage or grade, indicating widespread SOAT expression in breast cancer. To analyze the
role of SOAT for breast cancer cell proliferation, T47D cells were stably transfected with
SOAT and incubated under increasing concentrations of estrone-3-sulfate (E1S) and
estradiol at physiologically relevant concentrations. Cell proliferation was significantly
increased by 10−9 M estradiol as well as by E1S with EC50 of 2.2 nM. In contrast,
T47D control cells showed 10-fold lower sensitivity to E1S stimulation with EC50 of
21.7 nM. The E1S-stimulated proliferation of SOAT-T47D cells was blocked by the SOAT
inhibitor 4-sulfooxymethylpyrene. In conclusion: The present study clearly demonstrates
expression of SOAT in breast cancer tissue with ductal localization. SOAT inhibition
can block the E1S-stimulated proliferation of T47D breast cancer cells, demonstrating
that SOAT is an interesting novel drug target from the group of E1S uptake carriers for
anti-proliferative breast cancer therapy.
Keywords: estrone-3-sulfate, T47D, breast cancer, SOAT, transport, proliferation, SLC10A6, sulfate steroid
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INTRODUCTION
Estrogens play a pivotal role in the development and proliferation
of hormone-dependent breast cancer, which represents the most
common type of cancer in women (Conner et al., 2008).
Estrogens act via nuclear ERs (Henderson et al., 1988) and the
selective ER modulator tamoxifen has been used successfully for
antiestrogen breast cancer therapy for four decades (Osborne,
1998). Despite a significant decline of free estrogens after
menopause, a high percentage of all hormone-dependent breast
cancer cases develop in this phase of life (Kenemans and Bosman,
2003). In contrast to free estrogens (E1 and E2), the sulfo-
conjugated steroid forms, in particular estrone-3-sulfate (E1S)
and DHEAS, persist at higher plasma concentrations even after
menopause (Rémy-Martin et al., 1983; Geisler, 2003). These
sulfo-conjugated steroids can be re-converted into active free
estrogens in breast cancer tissue via cleavage of the sulfate
group by the STS and further conversion by the enzymes 3β-
hydroxysteroid dehydrogenase and aromatase in the case of
DHEA (Santner et al., 1986; Pasqualini et al., 1997; Labrie et al.,
1998; Suzuki et al., 2005; Sasano et al., 2006). Inhibitors of STS
(STX64) and aromatase (anastrozole, letrozole) can block this
intracrine formation of estrogens and, therefore, are used for
clinical (aromatase inhibitors) or experimental (STS inhibitors)
breast cancer therapy (Santen and Harvey, 1999; Stanway et al.,
2007).
Prior to intracellular conversion of E1S and DHEAS, these
negatively charged hydrophilic molecules first have to enter
breast cancer cells via carrier-mediated uptake. Several uptake
transporters for sulfo-conjugated steroid hormones have been
characterized so far, including members of the OATP and
the OAT families (Roth et al., 2012; Müller et al., 2015).
Most of these OATP/OAT carriers are multi-specific and are
involved in the transport of drugs, drug conjugates, bile
salts, and some other charged molecules (Burckhardt, 2012;
Hagenbuch and Stieger, 2013). Some of them are even expressed
in breast cancer tissue or breast cancer cell lines, including
OATP1A2, OATP1B3, OATP2B1, OATP3A1, OATP4A1, and
others, thus making them candidates for steroid sulfate uptake
in breast cancer (Pressler et al., 2011; Obaidat et al., 2012;
Nakanishi and Tamai, 2014).
In the present study, we analyzed expression of the SOAT
(gene name SLC10A6) in breast cancer. This carrier transports
all physiologically occurring sulfo-conjugated steroid hormones,
including E1S (Km of 12 µM), DHEAS (Km of 29 µM) and many
others (Geyer et al., 2007; Fietz et al., 2013; Grosser et al., 2018).
In contrast, free steroids, steroid glucuronides, or bile salts are not
transported by SOAT. Therefore, this carrier can be regarded as
highly specialized for sulfo-conjugated steroid hormones (Geyer
Abbreviations: 4-SMP, 4-sulfooxymethylpyrene; DCC, dextran-coated charcoal;
DHEAS, dehydroepiandrosterone sulfate; DMEM, Dulbecco’s Modified Eagle’s
Medium; DMSO, dimethyl sulfoxide; E1, estrone; E2, estradiol; E1S, estrone-3-
sulfate; ER, estrogen receptor; FCS, fetal calf serum; HER2, human epidermal
growth factor receptor 2; IHC, immunohistochemistry; LC-MS-MS, liquid
chromatography-tandem mass spectrometry; OAT, organic anion transporter;
OATP, organic anion transporting polypeptide; PBS, phosphate buffered saline; PR,
progesterone receptor; SOAT, sodium-dependent organic anion transporter; STS,
steroid sulfatase; TN, triple negative.
et al., 2007; Grosser et al., 2018), distinguishing it from OATPs
and OATs. Another difference to the OATP/OAT carriers is
the fact that SOAT mediates a secondary active transport of
its substrates. SOAT is highly expressed in germ cells of the
testis of men and mice (Fietz et al., 2013; Grosser et al., 2013).
Here, the SOAT-mediated import of sulfo-conjugated steroid
hormones was suggested to participate in the overall regulation
of spermatogenesis and fertility (Fietz et al., 2013; Grosser et al.,
2013; Bakhaus et al., 2018). In addition, relatively high SOAT
expression was detected in pancreas, placenta, and mammary
gland (Geyer et al., 2007).
In the present study, high SOAT mRNA expression was
found in a large set of breast cancer specimen. The SOAT
protein was localized in the normal ductal epithelium of the
breast and strong SOAT expression was found in breast biopsies
with different pathologies. Hormone-dependent breast cancer
T47D cells, stably transfected with SOAT, showed significant
proliferation after incubation with E1S at physiologically
relevant concentrations. This proliferation could be blocked
successfully by SOAT inhibition, demonstrating that SOAT
could be regarded as an interesting new drug target from the
group of E1S uptake carriers for antiproliferative breast cancer
therapy.
MATERIALS AND METHODS
Materials and Chemicals
All of the chemicals, unless otherwise stated, were from
Sigma-Aldrich (Taufkirchen, Germany). The compound 4-SMP
was kindly provided by Prof. Dr. Hansruedi Glatt (Potsdam-
Rehbrücke). [3H]estrone-3-sulfate ([3H]E1S, 57 Ci/mmol) was
purchased from PerkinElmer (Boston, MA, United States) and
[methyl-3H]thymidine (79 Ci/mmol) was obtained from GE
Healthcare (Amersham, United Kingdom). TissueScanTM breast
cancer cDNA arrays I-IV (BCRT101-BCRT104) were obtained
from OriGene (Rockville, MD, United States).
Breast Cancer cDNA Arrays
In order to analyze SOAT expression in breast cancer,
the following TissueScanTM cDNA arrays were commercially
obtained from OriGene (Rockville, MD, United States): Breast
Cancer cDNA Array I (BCRT101), Breast Cancer cDNA Array
II (BCRT102), Breast Cancer cDNA Array III (BCRT103), and
Breast Cancer cDNA Array IV (BCRT104). Each array contains
48 samples covering tumors of different histopathology, stages
and grades. For each tumor cDNA, detailed information is
available online1, including age, gender and ethnicity of the
patient, as well as diagnosis, pathology report, histologic type,
tissue images, tumor grade (based on the Nottingham grading
system, Elston and Ellis, 1991) and tumor stage (according to
the American Joint Committee on Cancer, 2002). In addition, the
receptor status is provided for the ER, PR, and HER2.
1https://www.origene.com/products/tissues/tissuescan
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Stable Transfection of T47D Cells With
the SOAT Construct
The human breast cancer cell line T47D (obtained from Dr.
Bernhard Ugele, Department of Gynecology and Obstetrics,
University Hospital Munich, Germany) was maintained in
a 1:1 mixture of DMEM and Ham’s F12 nutrient mixture
(Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS,
L-glutamine (4 mM), penicillin (100 units/ml), and streptomycin
(100 g/ml) at 37◦C, 5% CO2, and 95% humidity. For stable
transfection of T47D cells, the full length SOAT coding sequence
(Geyer et al., 2007) was subcloned into the pcDNA3.1 vector
(Invitrogen) using HindIII and XbaI restriction sites. The SOAT-
pcDNA3 vector was verified by DNA sequencing and used for
stable transfection of T47D cells by electroporation. Briefly,
subconfluent T47D cells were trypsinized and resuspended in
PBS containing 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4,
and 7.3 mM Na2HPO4 at pH 7.4. Approximately 106 cells
were transferred to a 4 mm Gene Pulser Cuvette (Bio-Rad
Laboratories, Munich, Germany), mixed with 20 µg plasmid and
incubated for 10 min on ice. The electroporation was performed
on the Gene Pulser Xcell System (Bio-Rad Laboratories) using
a single electrical pulse with initial field strength of 120 V,
discharged from the 960 µF capacitor and time constant of
10 ms. After an additional 10 min of incubation on ice, cells
were plated onto 10 cm culture dishes. After 24 h, selection
medium was added containing 750 µg/ml G418 sulfate and cells
were further incubated, changing the medium every 3 days.
After 12 days, several cell clones were pooled from the culture
dishes (T47D-SOAT) and SOAT expression was analyzed by
real-time PCR analysis. For control, T47D cells were also
transfected with an empty pcDNA3.1 vector. These T47D-control
cells were processed in the same manner as the T47D-SOAT
cells.
Expression Analysis by Real-Time PCR
TissueScanTM breast cancer cDNA arrays were directly used
for expression analysis of SOAT by real-time PCR. Symplekin
(SYMPK, Uniprot Q92797) that showed particularly low
expression variability in breast cancer tissue and cell lines (Tilli
et al., 2016) was used as endogenous control. RNA was isolated
from T47D-SOAT and T47D-control cells grown in 10 cm petri
dishes under DMEM/F12 medium. Cells were seeded at 106 cells
per well for each cell type and RNA was isolated following 72 h
of growth. The medium and any detached cells were removed
from the wells. Total RNA isolation was performed by using
the peqGOLD RNAPure reagent (PeqLab, Erlangen, Germany)
according to the manufacturer’s instructions. The isolated RNA
was dissolved in diethylpyrocarbonate-treated water and stored
at −80◦C until use. The RNA concentration was determined
by measuring absorbance at 260 nm with a Beckmann
spectrophotometer DU-640 (Beckmann, Munich, Germany).
Complementary cDNA was synthesized from the RNA samples
using the Advantage RT-for-PCR kit (BD Clontech, Heidelberg,
Germany) according to the manufacturer’s instructions. For
real-time PCR expression analysis of T47D cells, beta-actin
was used as endogenous control. Relative gene expression
analysis was performed by real-time PCR amplification on
an ABI PRISM 7300 thermal cycler (Applied Biosystems,
Darmstadt, Germany) using the TaqMan Gene Expression Assays
(Applied Biosystems, Darmstadt, Germany) Hs01399354_m1
for SOAT, Hs00165853_m1 for STS, Hs00174860_m1 for
ERα, Hs99999903_m1 for beta-actin, and Hs00191361_m1
for SYMPK. Real-time amplification was performed in 96-
well optical plates using 5 µl cDNA, 1.25 µl TaqMan Gene
Expression Assay, 12.5 µl TaqMan Universal PCR Master Mix
and 6.25 µl water in each 25 µl reaction. The plates were
heated for 10 min at 95◦C, and 45 cycles of 15 s at 95◦C
and 60 s at 60◦C were applied. Relative expression (1CT) was
calculated by subtracting the signal threshold cycle (CT) of
the endogenous control from the CT value of the respective
target.
Transport Assays in T47D Cells
For transport studies, 12-well plates were coated with poly-
L-lysine for better attachment of the cells. Twenty thousand
cells/well were plated and grown under DMEM/F12 medium
for 3 days. Before starting the transport experiments, T47D
cells were washed three times with PBS and incubated with
sodium transport buffer containing 142.9 mM NaCl, 4.7 mM
KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1.8 mM CaCl2, and
20 mM HEPES (pH 7.4). When transport assays were performed
in sodium-free transport buffer, sodium chloride was substituted
with equimolar concentrations of choline chloride. T47D-SOAT
and T47D-control cells were incubated with 250 µl of transport
buffer containing radiolabeled [3H]estrone-3-sulfate ([3H]E1S)
at 37◦C for 30 min. Transport assays were terminated by
removing the transport buffer and washing five times with ice-
cold PBS. Cell monolayers were lysed in 1 N NaOH with 0.1%
SDS, and the cell-associated radioactivity was determined in a
Wallac 1409 liquid scintillation counter (Pharmacia, Freiburg,
Germany). The protein content was determined according to
Lowry et al. (1951) using aliquots of the lysed cells with
bovine serum albumin as a standard. LC-MS/MS was used to
measure E1S concentrations in the cell culture medium at the
end of the uptake phase as described before (Galuska et al.,
2013).
Cell Proliferation Assays in T47D Cells
T47D cells were grown for at least 1 week in DMEM/F12
supplemented with 10% FCS. Then, for proliferation assays,
the cells were starved for 4 days in steroid-free phenol red-
free DMEM/F12 medium supplemented with 5% dextran-coated
charcoal-treated FCS (DCC-FCS). DCC-FCS was prepared by
incubating 0.5 g DCC in 100 ml FCS over 24 h at 4◦C, followed
by filtration (pleated filter MN 615 1/4, Macherey-Nagel, Düren,
Germany). T47D cells were plated at a density of 10,000 or
20,000 cells/well in 24-well plates. Twenty four hour after seeding,
E2 (final concentration 10−9 M) or E1S (final concentrations
10−12 to 10−4 M) were added from stock solutions containing
DMSO, considering that the final DMSO concentration in the
medium was below 0.1%, and cells were incubated at 37◦C, 5%
CO2, and 95% humidity. The negative control included solvent
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alone. Seven days after seeding, cells were treated with [methyl-
3H]thymidine with final concentrations of 1 µCi/ml at 37◦C
for 2 h as reported (Chalbos et al., 1982). After incubation, the
medium was removed and cells were washed five times with ice-
cold PBS. Then, cell lysis was performed with 500 µl of 1 N
NaOH and the radioactivity of the lysates was determined by
liquid scintillation counting.
Detection of SOAT in Breast Tissues by
Immunohistochemistry
Immunohistochemistry was performed on breast biopsies
of different pathologies, i.e., intraductal papilloma, atypical
ductal hyperplasia, intraductal carcinoma, and invasive ductal
carcinoma. Paraffin-embedded tissue slides were prepared at
the Department of Pathology at Atatürk University. Use of
human tissue was approved by the ethics committee of Atatürk
University, School of Medicine, No: 4/22, 02.06.2015. Tissue
sections were incubated with the primary antibody SLC10A6 (C-
13) (sc-136875, Santa Cruz, Dallas, TX, United States) at 1:100
dilution, followed by incubation with biotinylated goat anti-
rabbit E0432 secondary antibody (Dako, Glostrup, Denmark)
at 1:200 dilution in tris-buffered saline. Afterward, sections
were incubated with the avidin-biotin complex (ABC Vectastain,
Vector, Burlingame, CA, United States) and developed with 3-
amino-9-ethylcarbazole (AEC, Biologo, Kronshagen, Germany).
Counterstaining was performed with hematoxylin and slides
were mounted with Kaiser’s glycerol gelatin (Merck, Darmstadt,
Germany). Validation of the SLC10A6 C-13 antibody and the
IHC protocol has been previously performed for human placenta
(Schweigmann et al., 2014).
Statistical Methods
Unless otherwise indicated, values are represented as
means ± SD. All graphs and calculations were prepared
using the GraphPad Prism software 6.07 (GraphPad Software, La
Jolla, CA, United States). Student’s unpaired t-test and one-way
ANOVA with Tukey’s multiple comparisons test was performed
to determine statistical significance. Differences were considered
significant at p < 0.05. The EC50 values were calculated by non-
linear regression analysis from sigmoidal dose-response curves.
RESULTS
SOAT mRNA Expression in Breast
Cancer Specimen
In order to analyze SOAT expression in different types of breast
cancer, the OriGene TissueScanTM Breast Cancer cDNA Arrays
I-IV were screened for SOAT expression by real-time PCR.
The arrays included 192 cDNAs from breast cancer samples
of different pathology, stages, grades, and receptor status. All
samples with pathology verification were included in the data
analysis shown in Figure 1. Samples without pathology (array
classification: within normal limits) were excluded from the
analysis. SOAT mRNA expression was normalized by SYMPK
expression, which has previously demonstrated particularly low
variability of expression in breast cancer tissue and cell lines (Tilli
et al., 2016). SOAT expression was undetectable only in very
few samples and showed large variability in the tumor samples
ranging from 1CT of 0.83 (very high expression) up to 1CT of
10 (very low expression). Nearly all tumor samples were classified
as breast adenocarcinoma, with the vast majority being ductal.
Only three cDNAs derived from ductal carcinoma in situ and
one sample was from a squamous cell carcinoma of the breast.
Interestingly, this squamous cell carcinoma showed extremely
high SOAT expression that was even higher than in human testis,
representing the organ with the highest physiological SOAT
expression in man (Geyer et al., 2007; Fietz et al., 2013). In order
to determine if SOAT mRNA expression correlates with tumor
grade, stage, or receptor status, sub-analyses were performed. As
indicated in Figure 1A, SOAT expression was not significantly
different between tumors with grades G1, G2, or G3, or between
tumors of different stages (I-IV). Furthermore, there was no
difference in SOAT expression in tumors with different ER, PR, or
HER2 status. Even in TN breast cancer samples, SOAT expression
was not different from the other groups (Figure 1B). Further
sub-analyses were performed in the adenocarcinoma samples
including age and ethnos (Figure 1C). No effect of age on the
SOAT mRNA expression of breast adenocarcinomas was detected
and SOAT expression was comparable between Caucasians and
African Americans.
SOAT expression was also analyzed in individual breast cancer
samples at the protein level with the SLC10A6 (SOAT) C-13
antibody by IHC. Whereas SOAT expression was relatively low in
the ductal epithelium of normal breast tissue (Figure 2A), strong
SOAT immunoreactivity was detected in ductal hyperplasia
(Figure 2B), intraductal papilloma (Figure 2C), atypical ductal
hyperplasia (Figure 2D), intraductal carcinoma (Figure 2E), and
invasive ductal carcinoma (Figure 2F).
Generation of Stably Transfected
T47D-SOAT Cells
In order to investigate the role of the carrier-mediated import
of E1S by SOAT for the proliferation of breast cancer cells, we
chose the breast cancer cell line T47D as an in vitro model. T47D
cells have previously been described as ER expressing and they
showed estrogen dependent proliferation after incubation with
E2 and E1S at physiologically relevant concentrations (Nozawa
et al., 2004). However, compared to breast cancer tissue (see
Figure 1), where SOAT expression could be readily detected and
quantified in nearly all specimen, SOAT expression was very
low in T47D-control cells and was at the border of detectability
(CT∼37.9) in the real-time PCR expression analysis. Therefore,
in the present study, T47D cells were stably transfected with the
SOAT-pcDNA3 construct in order to increase SOAT expression
and mimic the situation in vivo. Different cell clones were pooled
from the culture dishes (further referred to as T47D-SOAT). As
control, T47D cells were transfected with an empty pcDNA3
vector (T47D-control). SOAT expression was analyzed by real-
time PCR and revealed significantly higher mRNA expression
levels in the T47D-SOAT cells compared with the T47D-control
cells (1CT = 5.4± 0.3 vs.1CT = 18.0± 0.5). In contrast, mRNA
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FIGURE 1 | SOAT mRNA expression in breast cancer. SOAT mRNA expression was analyzed in the TissueScanTM Breast Cancer cDNA Arrays I-IV, including 176
tumor cDNAs with different classifications (histopathology, grade, stage, and receptor status). Expression of SYMPK was used as endogenous control and 1CT
values are depicted at the y-axis. A cut-off was set at CT of 40. Sub-analyses were performed, including (A) tumor grade and stage, (B) receptor status for ER, PR,
HER2 and triple negative breast cancer (TN), and (C) age and ethnos. As the cDNA arrays were not equally distributed for the analyzed subgroups, every single
value is depicted for better clarity and additional box-whiskers-plots are given. For analysis of statistical significance, one-way ANOVA with Tukey’s multiple
comparisons test was performed. Differences with p < 0.05 were not detected.
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FIGURE 2 | Expression of the SOAT protein in breast cancer specimen.
Expression of the SOAT protein was analyzed in different breast cancer
specimen by IHC with the SOAT C-13 antibody (1:100 dilution, AEC staining,
hematoxylin counter stain), primary magnification × 40. Insets: Negative
control without the primary antibody, primary magnification × 40. (A) SOAT
expression in the ductal epithelium of normal breast tissue. (B) Strong SOAT
immunoreactivity of the ductal epithelium in usual ductal hyperplasia.
(C) Expression of SOAT in intraductal papilloma and expression along the
ductal epithelium with strong apical lining. (D) Strong SOAT immunoreactivity
in atypical ductal hyperplasia. (E) Severe immunolabeling with the SOAT
antibody in intraductal carcinoma. (F) Invasive ductal carcinoma with strong
and widespread SOAT expression.
expression levels of STS (1CT = 10.4 ± 0.4 vs. 1CT = 9.7 ± 1.2)
and ERα (1CT = 5.2 ± 0.3 vs. 1CT = 5.5 ± 0.7) were not
significantly different between T47D-SOAT and T47D-control
cells.
Transport Studies in SOAT-Transfected
T47D Cells
In order to verify functional SOAT carrier expression in
the cell membrane of the T47D-SOAT cells, we performed
transport experiments with [3H]E1S as substrate under both
sodium and sodium-free conditions. The uptake of 100 nM E1S
significantly increased over time in the T47D-SOAT cells only
in the presence of sodium, demonstrating significant sodium-
dependent uptake, which is a clear characteristic of SOAT. T47D-
control cell showed slightly higher E1S uptake in the presence
of sodium compared to sodium-free conditions, but without
reaching the level of significance (Figure 3A). At a physiologically
relevant concentration of 10 nM, T47D-SOAT cells also showed
significantly higher sodium-dependent uptake of E1S compared
FIGURE 3 | Sodium-dependent uptake of E1S into T47D-SOAT cells.
(A) T47D-SOAT and T47D-control cells were incubated with 100 nM [3H]E1S
at 37◦C in transport buffer containing Na+ or without Na+ (sodium-free
control). Cell-associated radioactivity was analyzed at the indicated time
points. (B) Transport of [3H]E1S at 10 nM over 30 min. Data in (A,B) represent
means ± SD of triplicate determinations. ∗Significantly higher transport
compared with T47D-control cells and the sodium-free controls (one-way
ANOVA with Tukey’s multiple comparisons test with p < 0.05).
(C) Determination of E1S concentrations by LC-MS/MS in the cell culture
medium at the end of the uptake phase. Data represent means ± SD of two
independent experiments, each with triplicate determinations. #Significantly
different between T47D-SOAT and T47D-control cells (unpaired t-test with
p < 0.05).
with T47D-control cells (Figure 3B). In order to verify that
under incubation with 10 nM E1S, this compound is indeed
taken up into the cells, an additional medium depletion assay
was performed and the E1S concentration was determined from
the medium at the end of incubation by means of LC-MS/MS.
As expected, the medium of the T47D-SOAT cells contained
significantly lower residue concentrations of E1S compared to the
medium of the T47D-control cells (Figure 3C).
E1S-Stimulated Proliferation of
T47D-SOAT Cells
In order to analyze the estrogen-dependent proliferation of
the transfected cell lines, T47D-SOAT and T47D-control cells
were grown in DCC-FCS medium supplemented with 10−9 M
E2 (positive control), increasing concentrations of E1S ranging
from 10−12 M to 10−4 M, or solvent alone (negative control).
Both cell lines showed significantly increased proliferation
Frontiers in Pharmacology | www.frontiersin.org 6 August 2018 | Volume 9 | Article 941
fphar-09-00941 August 18, 2018 Time: 18:56 # 7
Karakus et al. SOAT Breast Cancer Cell Proliferation
FIGURE 4 | E1S-dependent proliferation of T47D-SOAT cells.
SOAT-transfected T47D cells (T47D-SOAT, filled bars in A, black squares in B)
and mock-transfected T47D cells (T47D-control, open bars in A, open
squares in B) were plated at 10,000 cells/well in 24-well plates and were
cultured in phenol red-free DMEM/F12 containing 5% DCC-FCS over 7 days.
The culturing medium was supplemented with 10−9 M E2 for positive control
or increasing concentrations of E1S ranging from 10−12 M to 10−4 M. For
negative control, cells were treated with solvent alone. Seven days after
seeding, the cells were incubated with 1 µCi/ml [3H]thymidine for 2 h at 37◦C,
5% CO2, and 95% humidity. After five cycles of washing with PBS, cells were
subjected to liquid scintillation counting. Data represent the means ± SD of
quadruplicate determinations of three independent experiments (n = 12).
(A) ∗Significantly higher [3H]thymidine incorporation compared with negative
control (one-way ANOVA with Tukey’s multiple comparisons test with
p < 0.05). #Significantly higher [3H]thymidine incorporation in T47D-SOAT
compared with T47D-control cells (p < 0.05, unpaired t-test). (B) Values were
fitted to concentration response curves by non-linear regression analysis.
Proliferation was determined relative to the top (100%) and bottom (0%)
values that were derived from the sigmoidal dose response calculation. The
EC50 values were 2.2 ± 0.3 nM and 21.7 ± 2.1 nM for the T47D-SOAT and
T47D-control cells, respectively. Data represent means ± SEM.
under E2 treatment and this proliferation occurred at equal
levels for the SOAT-T47D and SOAT-control cells (Figure 4A).
After treatment with E1S at increasing concentrations, both
cell lines showed increased proliferation, but with different
profiles. Beginning at 10−11 M E1S, T47D-SOAT cells showed
significantly enhanced proliferation compared to T47D-control
cells with a maximum proliferation at 10−7 M. In contrast, T47D-
control cells did not start to proliferate until 10−9 M E1S and
required 10−6 M E1S for maximum proliferation (Figure 4A).
Within the concentration range of 10−11 to 10−8 M E1S, T47D-
SOAT showed significantly higher proliferation compared to
T47D-control cells. Half-maximal stimulation (ED50) of the E1S-
stimulated proliferation occurred at concentrations of 2.2 nM and
FIGURE 5 | Inhibition of the E1S-dependent proliferation of T47D-SOAT cells.
Stably SOAT-transfected T47D cells (T47D-SOAT) and mock-transfected
T47D cells (T47D-control) were plated at 20,000 cells/well in 24-well plates
and were cultured in phenol red-free DMEM/F12 containing 5% DCC-FCS.
The culturing medium was supplemented with 10−8 M E1S, 10−9 M E2 or
solvent alone (control). Additionally, 25 µM of the SOAT inhibitor 4-SMP were
added to the culturing medium as indicated. After 6 days of cultivation, the
cells were incubated with 1 µCi/ml [3H]thymidine for 2 h at 37◦C, 5% CO2,
and 95% humidity. After five cycles of washing with PBS, cells were subjected
to liquid scintillation counting. Data represent means ± SD of quadruplicate
determinations of a representative experiment. ∗Significantly different from
solvent control (one-way ANOVA with Tukey’s multiple comparisons test with
p < 0.05). #Significantly higher [3H]thymidine incorporation in T47D-SOAT
compared with T47D-control cells (p < 0.05, unpaired t-test).
21.7 nM for the T47D-SOAT and T47D-control cells, respectively
(Figure 4B). This indicates that SOAT-mediated transport of E1S
at physiologically relevant concentrations significantly stimulated
the proliferation of T47D cells.
In order to block this increased proliferation via SOAT, 4-
SMP was used as an inhibitor. 4-SMP proved to be one of the
most potent inhibitors of SOAT in a previous study (Geyer et al.,
2007). Indeed, incubation of T47D-SOAT cells with 25 µM 4-
SMP completely blocked cell proliferation by E1S (Figure 5),
while 4-SMP alone had no effect on the cell proliferation of
T47D-SOAT and T47D-control cells. Furthermore, 4-SMP had
no effect on the E2-stimulated cell proliferation of T47D-SOAT
cells, which occurs independent from SOAT-mediated transport
(Figure 5, right panel).
In further experiments, the time course of E1S-stimulated
T47D cell proliferation was analyzed in further detail with and
without 4-SMP as inhibitor of SOAT. Both cell lines, T47D-SOAT
and T47D-control, significantly increased their proliferation
from days 4 to 6 under incubation with 10 nM E1S, but at day
6, T47D-SOAT cells showed significantly higher [3H]thymidine
incorporation compared with the T47D-control cells. In cells
additionally incubated with 4-SMP, proliferation was blocked
and was not different from the control groups without E1S
incubation (Figure 6). Again, 4-SMP alone had no effect on cell
proliferation.
DISCUSSION
As has been known for a long time, breast tumor tissue is
able to metabolize steroids from sulfated precursors, which are
available even after menopause, to biologically active estrogens
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FIGURE 6 | Time course of the E1S-dependent proliferation of T47D-SOAT
cells. T47D-SOAT and T47D-control cells were plated at 20,000 cells/well in
24-well plates and were cultured in phenol red-free DMEM/F12 containing 5%
DCC-FCS. The culturing medium was supplemented with 10−8 M E1S,
25 µM 4-SMP or solvent alone. Additionally, 10−8 M E1S were incubated
together with the SOAT inhibitor 4-SMP at 25 µM. After 2, 3, 4, 5, and 6 days
of cultivation, the cells were incubated with 1 µCi/ml [3H]thymidine for 2 h at
37◦C, 5% CO2, and 95% humidity. After five cycles of washing with PBS, cells
were subjected to liquid scintillation counting. Data represent the means ± SD
of quadruplicate determinations of a representative experiment. ∗Significant
increase compared to day 2 (p < 0.05, one-way ANOVA with Tukey’s multiple
comparisons test). #Significantly higher [3H]thymidine incorporation in
T47D-SOAT compared to T47D-control cells (p < 0.05, unpaired t-test).
(Adams and Wong, 1968; Miller and Forrest, 1976). Most
studies in this field focus on the metabolic steps involved in
estrogen formation, and simply presume intracellular availability
of the mostly sulfated precursors (Labrie et al., 2001). However,
sulfo-conjugated steroids are negatively charged molecules and
can only enter target cells via carrier-mediated uptake (Müller
et al., 2015). Therefore, several previous studies have investigated
the expression of uptake carriers for sulfated steroids in the
normal mammary gland and breast cancer tissue, including
OATP1A2, OATP2B1, OATP3A1, OATP4A1, and OATP1B3
(Pizzagalli et al., 2003; Miki et al., 2006; Meyer zu Schwabedissen
et al., 2008; Wlcek et al., 2008; Kindla et al., 2011; Banerjee
et al., 2014). Furthermore, E1S uptake carrier expression was
demonstrated in different hormone-dependent breast cancer cell
lines, such as OATP1A2, OATP3A1, and OATP4A1 in T47D
cells (Nozawa et al., 2004, 2005; Meyer zu Schwabedissen et al.,
2008) as well as OATP1A2, OATP2B1, OATP3A1, and OATP4A1
in MCF7 cells (Nozawa et al., 2005; Meyer zu Schwabedissen
et al., 2008; Wlcek et al., 2008; Maeda et al., 2010; Stute
et al., 2012; Banerjee et al., 2012, 2013, 2015; Matsumoto
et al., 2015). Overall these studies demonstrated that carrier-
mediated import of E1S in breast cancer cells can stimulate
their proliferation and thus these carriers were suggested as
potential drug targets (Obaidat et al., 2012; Nakanishi and Tamai,
2014).
In the present study, we only focused on the expression
of SOAT in breast cancer and aimed to analyze its role for
hormone-dependent proliferation. SOAT was first cloned from
rat adrenal gland and demonstrated significant transport of
E1S and DHEAS (Geyer et al., 2004). Later, the human SOAT
transcript was cloned (Geyer et al., 2007). The substrate spectrum
of SOAT was intensively analyzed and revealed specific transport
of all physiologically occurring sulfo-conjugated steroid
hormones, being E1S, 17β-estradiol-3-sulfate, 17β-estradiol-17-
sulfate, pregnenolone sulfate, 17α-OH-pregnenolone sulfate,
androsterone sulfate, epiandrosterone sulfate, testosterone
sulfate, epitestosterone sulfate, 5α-dihydrotestosterone
sulfate, androstenediol sulfate, DHEAS, and 16α-OH-
DHEAS (Geyer et al., 2007; Fietz et al., 2013; Schweigmann
et al., 2014; Grosser et al., 2018). Sulfo-conjugated bile salts,
bromosulfophthalein (BSP, a dye used in liver function tests), and
the sulfooxymethylpyrenes 2-SMP and 4-SMP were identified as
effective SOAT inhibitors (Geyer et al., 2007). Apart from high
SOAT expression in the testis, placenta, lung and skin, SOAT
also showed relatively high mRNA expression in the mammary
gland (Geyer et al., 2007). Here, in the present study the SOAT
protein was localized to the ductal epithelium (Figure 2). Based
on this data, it was not surprising that SOAT showed high
expression in different pathologies of the breast with a clear
ductal staining pattern in IHC, including ductal hyperplasia,
intraductal papilloma and intraductal carcinoma (Figure 2). It
can be supposed that, in addition to other E1S carriers from
the OATP family, SOAT expression in ductal hyperplasia and
intraductal carcinoma contributes to the import of E1S (and
probably also E2S) and therefore provides the precursors for
the intracrine formation of pro-proliferative E2. Based on this
mechanism, SOAT can be regarded as an additional drug target
for anti-proliferative breast cancer therapy from the group of
E1S uptake carriers. Against this background, it is interesting to
note that SOAT expression was detected in a wide range of breast
cancer specimen. Most of them represent adenocarcinoma of
the breast with ductal localization (Figure 1). SOAT expression
does not correlate with tumor stage, grade or receptor status.
Therefore, SOAT might be an interesting drug target in a wide
variety of breast tumors.
In order to verify the role of SOAT for the E1S-dependent
proliferation of breast cancer cells, we intended to generate an
in vitromodel that mimics the in vivo situation as near as possible.
Different ER positive breast cancer cell lines such as T47D
and MCF7 have emerged as in vitro models for proliferation
studies in the past (MacIndoe, 1988; Pasqualini et al., 1990; Evans
et al., 1993; Billich et al., 2000; Schmitt et al., 2001; Maggiolini
et al., 2001, 2002). Of those, we used T47D cells, as their
intracrine estrogen synthesis is well characterized and E1S uptake
carrier expression has been investigated previously on these cells
(Pizzagalli et al., 2003; Nozawa et al., 2004; Miki et al., 2006).
However, as demonstrated by real-time PCR, SOAT expression
seems to be down-regulated in T47D cells compared to breast
cancer tissue. Therefore, we generated a SOAT-transfected T47D-
SOAT cell line as well as a mock-transfected T47D-control
cell line for proliferation assays. In the T47D-SOAT cells, high
SOAT mRNA expression was confirmed by real-time PCR at the
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transcriptional level as well as by significant sodium-dependent
transport of [3H]E1S at the level of the active transporter
protein (Figure 3). For proliferation studies, these T47D-SOAT
cells were incubated under increasing concentrations of E1S
at 10−12 to 10−4 M. As previously described (Nozawa et al.,
2004), proliferation of T47D cells can be stimulated not only
by E2, but also by E1S at higher concentrations. In the present
study, we obtained a sigmoidal dose-response curve with an
effective concentration (EC50) of 21.7 nM for the T47D-control
cells, which is very close to previous data, being 17.1 nM
(Nozawa et al., 2004). Interestingly, proliferation of the SOAT-
expressing T47D-SOAT cells was stimulated already at much
lower E1S concentrations and the dose-response curve revealed
an EC50 of 2.2 nM, meaning a 10-fold increased sensitivity
to E1S exposure. At physiological E1S concentrations, being in
the order 10−8 to 10−9 M (Pasqualini, 2004), the differences
between the proliferations of T47D-SOAT vs. T47D-control cells
were most pronounced (Figure 4). To ensure that this increased
proliferation is indeed induced by SOAT-mediated import of E1S,
the cells were co-incubated with E1S and the SOAT inhibitor
4-SMP (Geyer et al., 2007). In these experiments, E1S was
added at 10 nM to stimulate cell proliferation, representing
a concentration at which T47D-SOAT cells showed significant
sodium-dependent transport activity for [3H]E1S. Interestingly,
4-SMP completely blocked the E1S-mediated proliferation of
T47D-SOAT cells and likewise that of T47D-control cells. To
verify that 4-SMP itself does not cause inhibition of proliferation
by any other effect than by inhibiting the E1S uptake, 4-SMP
was additionally co-incubated with E2. In these experiments,
the E2-stimulated proliferation of the T47D-SOAT cells was not
affected by 4-SMP, indicating that 4-SMP had no effect on the
direct estrogenic effect of E2, but only on the transport of E1S.
The inhibiting effect of 4-SMP on the T47D-control cells could
mean that here, residue E1S transport activity is inhibited even if
SOAT is expressed at very low levels in the T47D-control cells.
Another explanation would be that 4-SMP inhibits other E1S
uptake transporters, such as OATP1A2, OATP2B1, OATP3A1,
and OATP4A1, which have been detected previously in T47D
cells (Pizzagalli et al., 2003; Nozawa et al., 2004; Miki et al.,
2006). At least in the case of OAT3, 4-SMP has been described
as inhibitor (Bakhiya et al., 2006), indicating that 4-SMP is
not selective for SOAT. However, if 4-SMP does interfere with
the E1S transport via one of the mentioned OATPs must be
elucidated.
CONCLUSION
The present study demonstrates expression of SOAT in breast
cancer tissue with ductal localization. SOAT inhibition can block
the E1S-stimulated proliferation of T47D breast cancer cells
and, therefore, in addition to the carriers of the OATP carrier
family, can be regarded as a novel potential drug target for
anti-proliferative breast cancer therapy. Very recently, novel
inhibitors of SOAT were identified by pharmacophore modeling
(Grosser et al., 2016). After optimization, these compounds are
interesting candidates for further breast cancer proliferation
studies in vitro and in vivo. These studies should also include
comparative transport inhibition of SOAT and carriers of the
OATP and OAT families in order to find at best an inhibitor for
E1S transport covering all uptake carriers in breast cancer cells.
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